公开(公告)号：US20210346478A1

公开(公告)日：2021-11-11

申请号：US17232751

申请日：2021-04-16

申请人： The Regents of the University of Michigan

发明人： Duxin Sun ,  Ryan Clauson ,  Hongwei Chen ,  Chengyi Li ,  Wei Gao ,  Luke Bugada ,  Fei Wen ,  Brett Hill ,  Syed Monem Rizvi

IPC分类号： A61K39/00 ,  A61K47/02 ,  A61K9/16 ,  A61K38/19 ,  A61K47/69 ,  A61K47/64 ,  A61K45/06 ,  A61K39/295 ,  A61P35/00 ,  A61K39/39

摘要： The present invention provides, in some embodiments, methods, compositions, systems, and kits comprising nano-satellite complexes comprising: a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; 3-25 satellite particles attached to, or absorbed to, said biocompatible coating; a plurality of antigenic peptides conjugated to, or absorbed to, said satellite particles; and at least one additional property. In other embodiments, provided herein are nano-satellite complexes comprising: a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; a plurality of satellite particles attached to, or absorbed to, said biocompatible coating; a plurality of antigenic peptides conjugated to, or absorbed to, said satellite particles; and a plurality of LIGHT (TNFSF14) peptides conjugated to, or absorbed to, said satellite particles. In some embodiments, administration of the nanosatellite complexes to a subject with cancer achieves long-term cancer remission (e.g., when combined with an immune checkpoint inhibitor, such as αPD1).

公开(公告)号：US11819516B2

公开(公告)日：2023-11-21

申请号：US15773952

申请日：2016-11-04

申请人： THE REGENTS OF THE UNIVERSITY OF MICHIGAN

发明人： Fei Wen ,  Mason Smith

IPC分类号： C12N15/62 ,  C12N5/0783 ,  C07K14/39 ,  A61K35/17 ,  A61K48/00 ,  A61K47/61 ,  A61K47/68 ,  A61K38/17 ,  C07K19/00

CPC分类号： A61K35/17 ,  A61K38/1774 ,  A61K47/61 ,  A61K47/6889 ,  A61K48/00 ,  C07K14/39 ,  C07K19/00 ,  C12N5/0636 ,  C12N15/62 ,  C07K2318/10 ,  C07K2319/02 ,  C07K2319/035

摘要： Provided herein is technology relating to immunotherapy and particularly, but not exclusively, to compositions, methods, and kits for immunotherapy and activation of T cells using a peptide-major histocompatibility complex (pMHC) assembled on a protein scaffold for patterned signal presentation of T cell activating ligands to T cells.

公开(公告)号：US11020470B2

公开(公告)日：2021-06-01

申请号：US15566069

申请日：2016-04-12

申请人： THE REGENTS OF THE UNIVERSITY OF MICHIGAN

发明人： Fei Wen ,  Eshita Khera ,  Brett Dallas Hill ,  Syed Rizvi

IPC分类号： A61K39/12 ,  C12N15/81 ,  A61K39/145 ,  A61K39/21 ,  C07K14/395 ,  A61K39/00

摘要： Provided herein are membrane enveloped virus-like particles (VLPs), and methods of use and synthesis thereof. In particular, yeast-cell-derived VLPs are provided that comprise surface-displayed glycoproteins and/or multiple virally-derived proteins.

公开(公告)号：US20240226104A1

公开(公告)日：2024-07-11

申请号：US18556250

申请日：2022-04-20

申请人： THE REGENTS OF THE UNIVERSITY OF MICHIGAN

发明人： Wei Gao ,  Duxin Sun ,  Fei Wen ,  Ruiting Li ,  Hongxiang Hu ,  Luke F. Bugada ,  Yudong Song ,  Mahamadou Djibo

IPC分类号： A61K31/519 ,  A61K9/00 ,  A61K9/51 ,  A61K31/337 ,  A61P35/04

CPC分类号： A61K31/519 ,  A61K9/0019 ,  A61K9/5169 ,  A61K31/337 ,  A61P35/04

摘要： The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors, and compositions, nanoformulations and methods for treating diseases or disorders (e.g., breast cancer, pancreatic cancer, lung cancer, and lymphoma) with PBK inhibitors or composition thereof. Disclosed herein is a composition comprising: an effective amount of a PI3K inhibitor or a pharmaceutically acceptable salt thereof; and an albumin nanoparticle.